Moreover, these compounds also displayed efficacy in rescuing processing and trafficking defects in rare CFTR mutants that are resistant to currently approved therapies, suggesting their potential for inclusion in next-generation combinatorial treatments for CF [169]. This evidence concerns the gene CFTR and cystic fibrosis.